Amgen (AMGN) Offering Possible 20.63% Return Over the Next 24 Calendar Days

Amgen's most recent trend suggests a bullish bias. One trading opportunity on Amgen is a Bull Put Spread using a strike $195.00 short put and a strike $185.00 long put offers a potential 20.63% return on risk over the next 24 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $195.00 by expiration. The full premium credit of $1.71 would be kept by the premium seller. The risk of $8.29 would be incurred if the stock dropped below the $185.00 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Amgen is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Amgen is bullish.

The RSI indicator is at 67.4 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Amgen

Which Big Pharma Stocks Lose Most in a War on Drug Price Hikes?
Sun, 20 Jan 2019 13:59:00 +0000
The answer: It's complicated.

See what the IHS Markit Score report has to say about Amgen Inc.
Sat, 19 Jan 2019 13:00:09 +0000
# Amgen Inc

### NASDAQ/NGS:AMGN

View full report here!

## Summary

* Perception of the company's creditworthiness is negative
* ETFs holding this stock are seeing positive inflows but are weakening
* Bearish sentiment is low

## Bearish sentiment

Short interest | Positive

Short interest is extremely low for AMGN with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting AMGN.

## Money flow

ETF/Index ownership | Negative

ETF activity is negative and may be weakening. The net inflows of $7.41 billion over the last one-month into ETFs that hold AMGN are among the lowest of the last year and appear to be slowing.

## Economic sentiment

PMI by IHS Markit | Neutral

According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing.

## Credit worthiness

Credit default swap | Negative

The current level displays a negative indicator. AMGN credit default swap spreads are near their highest levels for the past 1 year, which indicates the market's more negative perception of the company's credit worthiness.

Please send all inquiries related to the report to score@ihsmarkit.com.

Charts and report PDFs will only be available for 30 days after publishing.

This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

Amgen (AMGN) Gains But Lags Market: What You Should Know
Fri, 18 Jan 2019 22:50:10 +0000
Amgen (AMGN) closed at $203.70 in the latest trading session, marking a +0.88% move from the prior day.

Should You Buy Amgen Inc. (NASDAQ:AMGN) For Its Dividend?
Fri, 18 Jan 2019 18:18:24 +0000
Dividends play a key role in compounding returns over time and can form a large part of our portfolio return. Historically, Amgen Inc. (NASDAQ:AMGN) has paid a dividend to shareholders.

Read More…

FDA Committee Recommends Amgen Drug — But A Key Question Lingers
Thu, 17 Jan 2019 21:06:05 +0000
A Food and Drug Administration committee voted late Wednesday to recommend Amgen's osteoporosis treatment — but to a narrow population. Amgen stock rose Thursday.

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.